Imagine a world where a common, affordable drug could turn the tide against one of the most stubborn forms of breast cancer. That’s exactly what researchers are now suggesting with dexamethasone, a drug you might recognize from its use in reducing inflammation. But here’s where it gets groundbreaking: this familiar medication might hold the key to halting metastases in hormone-resistant breast cancer, a challenge that has long baffled oncologists. A recent study published in EMBO Press (https://www.embopress.org/doi/full/10.1038/s44321-025-00342-z) by scientists at the University of Basel (https://www.unibas.ch/en.html) reveals that dexamethasone, a synthetic version of the body’s stress hormone cortisol, could do more than just ease side effects—it might directly combat treatment-resistant metastases in estrogen receptor-positive (ER+) breast cancer. And this is the part most people miss: it’s not just about repurposing a drug; it’s about unlocking a new frontier in personalized cancer treatment.
Reimagining a Household Name in Medicine
Dexamethasone has long been a go-to for its anti-inflammatory and immunosuppressive properties, often prescribed to manage swelling, allergies, and even chemotherapy side effects. But its potential as a cancer-fighting agent? That’s a relatively new and exciting development. For ER+ breast cancer, the usual approach involves anti-hormonal therapies that target the estrogen receptor, a protein that, when overactive, fuels uncontrolled cell growth. While effective for many, some patients develop resistant metastases, rendering these treatments ineffective. This is where dexamethasone steps in—not as a replacement, but as a potential game-changer.
Promising Results in Preclinical Models
In lab studies, researchers tested dexamethasone on mice with hormone therapy-resistant ER+ tumors. The results were striking: the drug significantly reduced liver metastases, and the treated mice lived longer than those in the control group. But how does it work? Dexamethasone activates the glucocorticoid receptor, which in turn suppresses the production of the estrogen receptor. As Dr. Madhuri Manivannan, the study’s lead author, explains, ‘This effectively removes the primary driver of tumor growth.’ It’s like cutting the fuel supply to a runaway engine.
From Mice to Men: Supporting Evidence
To bridge the gap between animal studies and human applications, the team turned to organoids—tiny, lab-grown tumor structures derived from patient tissues. When exposed to dexamethasone, these organoids showed a similar reduction in estrogen receptor levels, mirroring the findings in mice. This dual validation strengthens the case for dexamethasone’s potential in human patients.
A Controversial Twist: Not a One-Size-Fits-All Solution
Here’s where it gets controversial: while dexamethasone shows promise for ER+ breast cancer, its effects vary wildly across different cancer types. Professor Mohamed Bentires-Alj of the University of Basel notes, ‘The same drug can have dramatically different impacts depending on the cancer subtype.’ This highlights the need for personalized treatment approaches—a reminder that in oncology, one size rarely fits all. Could this variability spark debates about the drug’s broader applicability? Absolutely. And that’s a conversation worth having.
The Road Ahead: From Lab to Clinic
Dr. Charly Jehanno, who led the study, is cautiously optimistic: ‘Dexamethasone could become more than just a supportive therapy for nausea and inflammation; it might directly enhance breast cancer treatments.’ But there’s a catch: these findings, particularly the suppression of the estrogen receptor, need to be confirmed in clinical trials. If successful, dexamethasone could be repurposed as a frontline weapon against metastases, offering hope to patients with limited options.
A Thought-Provoking Question for You
As we stand on the brink of potentially repurposing a decades-old drug for a modern cancer challenge, it’s worth asking: How might this shift our approach to drug development? Should we focus more on repurposing existing medications rather than always chasing new compounds? Share your thoughts in the comments—let’s spark a conversation that could shape the future of cancer treatment.
